Spravato vs. Seroquel: Ketamine Wins Big in Head-to-Head Depression Battle

Dr. Tracy Marks discusses ketamine's role in treating depression, highlighting its rapid effects and recent developments. Ketamine, traditionally an anesthetic, is now recognized for its antidepressant properties, especially for treatment-resistant depression. The FDA-approved nasal spray Spravato has shown superior results compared to quetiapine. Despite initial skepticism, Spravato's effectiveness and potential insurance coverage make it a viable option. Recent studies also support ketamine injections as a cost-effective alternative. The video concludes with a look at future treatments like psilocybin.

What are some side effects of Spravato compared to quetiapine?

What are the potential implications of the findings on ketamine for individuals with chronic depression?

What does the recent research suggest about the safety and effectiveness of ketamine injections?